Progress in CLL therapy during the last decade by combining different agents. The figure shows approximate rates of complete remissions and overall responses in CLL first line treatment as reported by recent randomized trials (see Tables 1–3Table 2,Table 3).
 F indicates fludarabine; C, cyclophosphamide; R, rituximab.